Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Cancer Cell - United States
doi 10.1016/j.ccr.2012.11.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Combined MEK and BCL-XL Inhibition Kills KRAS -Mutant Cells

Cancer Discovery
Oncology
2012English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

MEK Nuclear Localization Promotes YAP Stability via Sequestering Β-TrCP in KRAS Mutant Cancer Cells

Cell Death and Differentiation
Cell BiologyMolecular Biology
2019English

Combined Inhibition of Notch Signaling and BCL-2/BCL-xL Results in Synergistic Antimyeloma Effect

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

Synthetic Lethal Interaction of CDK Inhibition and Autophagy Inhibition in Human Solid Cancer Cell Lines

Oncology Reports
MedicineCancer ResearchOncology
2017English

Apoptosis Is Augmented in High-Grade Serous Ovarian Cancer by the Combined Inhibition of BCL-2/BCL-xL and PARP

International Journal of Oncology
Cancer ResearchOncology
2017English

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

PLoS ONE
Multidisciplinary
2016English

Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers

Nature
Multidisciplinary
2013English

SHP2 Inhibition Overcomes RTK-mediated Pathway Re-Activation in KRAS Mutant Tumors Treated With MEK Inhibitors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy